Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation

American Journal of Cardiology

Volumn 84, Issue 9, 1999, Pages 1033-1037

  Vincenzo De Paola, Angelo Amato ^a   Veloso, Henrique Horta ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; QUINIDINE; SOTALOL;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURETIC THERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SINUS RHYTHM; TREATMENT PLANNING;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINIDINE; RECURRENCE; SOTALOL; TREATMENT OUTCOME;

EID: 0344631777     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00494-4     Document Type: Article

References (31)

1. Coplen S.E., Antman E.M., Berlin J.A., Hewitt P., Chalmers T.C. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 82:1990;1106-1116.
2. Reimold S.C., Chalmers T.C., Berlin J.A., Antman E.M. Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation observations on the role of trial design and implications of drug-related mortality . Am Heart J. 124:1992;924-932.
3. Brodsky M.A., Chun J.G., Podrid P.J., Douban S., Allen B.J., Cygan R. Regional attitudes of generalists, specialists and subspecialists about management of atrial fibrillation. Arch Intern Med. 156:1996;2553-2562.
4. Jung F., DiMarco J.P. Antiarrhythmic drug therapy in the treatment of atrial fibrillation. Cardiol Clin. 14:1996;507-520.
5. Antman E.M., Beamer A.D., Cantillon C., McGowan N., Friedman P.L. Therapy of refractory symptomatic atrial fibrillation and atrial flutter a staged care approach with new antiarrhythmic drugs . J Am Coll Cardiol. 15:1990;698-707.
6. Juul-Möller S., Edvardsson N., Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 82:1990;1932-1939.
7. Reimold S.C., Cantillon C.O., Friedman P.L., Antman E.M. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 71:1993;558-563.
8. Hohnloser S.H., van de Loo A., Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation prospective comparison of sotalol versus quinidine . J Am Coll Cardiol. 26:1995;852-858.
9. Bellandi F., Dabizzi R.P., Niccoli L., Cantini F., Palchetti R. Propafenone and sotalol long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. Double blind placebo-controlled study . G Ital Cardiol. 26:1996;379-390.
10. Wanless R.S., Anderson K., Joy M., Joseph S.P. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 133:1997;441-446.
11. Gallik D.M., Kim S.G., Ferrick K.J., Roth J.A., Fisher J.D. Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. Am Heart J. 134:1997;155-160.
12. Alt E., Ammer R., Lehmann G., Pütter K., Ayers G.M., Pasquantonio J., Schömig A. Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with sotalol. Am Heart J. 134:1997;419-425.
13. Kochiadakis G.E., Igoumenidis N.E., Marketou M.E., Solomou M.C., Kanoupakis E.M., Vardas P.E. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 81:1998;995-998.
14. Mary-Rabine L., Albert A., Pham T.D., Hordof A., Fenoglio J.J. Jr, Malm J.R., Rosen M.R. The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure. Circ Res. 52:1983;188-199.
15. Vitolo E., Tronci M., Larovere M.T., Rumolo R., Morabito A. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol. 36:1981;431-444.
16. Veltri E.P., Reid P.R. Amiodarone pulmonary toxicity early changes in pulmonary function tests during amiodarone rechallenge . J Am Coll Cardiol. 6:1985;802-805.
17. Mason J.W. Amiodarone. N Engl J Med. 316:1987;455-466.
18. Albert S.G., Alves L.E., Rose E.P. Thyroid dysfunction during chronic amiodarone therapy. J Am Coll Cardiol. 9:1987;175-183.
19. Brodsky M.A., Allen B.J., Walker C.J., Casey T.P., Luchet C.R., Henry W.L. Amiodarone for the maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated atrium. Am J Cardiol. 60:1987;572-575.
20. Gold R.L., Haffajee C.I., Charos G., Sloan K., Baker S., Alpert J.S. Amiodarone for refractory atrial fibrillation. Am J Cardiol. 57:1986;124-127.
21. Waris E., Kreus K.E., Salokannel J. Factors influencing persistence of sinus rhythm after DC shock treatment of atrial fibrillation. Acta Med Scand. 189:1971;161-166.
22. Ewy G.A., Ulfers L., Hager H.D., Rosenfeld A.R., Roeske W.R., Goldman S. Response of atrial fibrillation to therapy role of etiology and left atrial diameter . Electrocardiology. 13:1980;119-124.
23. Singh S., Saini R.K., DiMarco J., Kluger J., Gold R., Chen Y. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation the Sotalol Study Group . Am J Cardiol. 68:1991;1227-1230.
24. Alboni P., Razzolini R., Scarfo S., Paperella N., Fuca G., Pedri I., Chioin R. Hemodynamic effects of oral sotalol during both sinus rhythm and atrial fibrillation. J Am Coll Cardiol. 22:1993;1373-1377.
25. Brodsky M., Saini R., Bellinger R., Zoble R., Weiss R., Powers L. Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation the dl-Sotalol Atrial Fibrillation Study Group . Am Heart J. 127:1994;572-577.
26. Grace A.A., Camm A.J. Quinidine. N Engl J Med. 338:1998;35-45.
27. Flaker G.C., Blackshear J.L., McBride R., Kronmal R.A., Halperin J.L., Hart R.G. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation the Stroke Prevention in Atrial Fibrillation Investigators . J Am Coll Cardiol. 20:1992;527-532.
28. Chung M.K., Schweikert R.A., Wilkoff B.L., Niebauer M.J., Pinski S.L., Trohman R.G., Kidwell G.A., Jaeger F.J., Morant V.A., Miller D.P., Tchou P.J. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol. 32:1998;169-176.
29. Hohnloser S.H., Zabel M., van de Loo A., Kligenheben T., Just H. Efficacy and safety of sotalol in patients with complex ventricular arrhythmias. Int J Cardiol. 37:1992;283-291.
30. Wyse K.R., Ye V., Campbell T.J. Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide implications for proarrhythmia due to triggered activity . J Cardiovasc Pharmacol. 21:1993;316-322.
31. The dl-Sotalol AFIB/AFL Multicenter Study Group. Efficacy, safety and dose-response study of dl-sotalol for prevention of recurrence of atrial fibrillation/atrial flutter (AFIB/AFL) (abstr). PACE 1998;21:II-812.